Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06080698 · ClinicalTrials.gov registry record · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
A NA study of Gram-negative Bacteremia, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- NA
- Development phase
- 1,030
- Enrollment target
- 11
- Study locations
NCT06080698: Recruiting NA study of Gram-negative Bacteremia, sponsored by Johns Hopkins University.
NCT06080698 is a NA study of Gram-negative Bacteremia that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 1,030 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06080698, a NA study of Gram-negative Bacteremia, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,030 participants
- Enrollment target
- 11
- Study locations
Study Summary
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.
Primary Outcome
Each participant will be placed in 1 of 5 DOOR levels based on overall clinical response and treatment-related adverse events (AE). The 5 DOOR levels are as follows: successful clinical response and no treatment-related AE (Level 1); mild suboptimal clinical response or mild treatment-related AE (Level 2); moderate suboptimal clinical response or moderate treatment-related AE (Level 3); significant suboptimal clinical response or significant treatment-related AE (Level 4); death (Level 5). The d
Conditions Studied
Interventions
- DRUG Intravenous Antibiotics
- DRUG Oral Antibiotics
Study Locations (11)
Maryland
- University of Maryland Medical Center - Baltimore
- Johns Hopkins University Hospital Systems - Baltimore
California
- University of California, San Francisco - San Francisco
Colorado
- Denver Health Hospital Authority - Denver
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Rutgers-RWJ University Hospital - New Brunswick
North Carolina
- Duke University - Durham
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,030 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT06080698 shows while recruiting
NCT06080698 is an interventional study that assigns participants to a tested intervention. Its 1,030 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Gram-negative Bacteremia appearing as the primary indexed condition, and to 2 interventions - of which Intravenous Antibiotics is the first listed.
NCT06080698 lists 11 locations in 10 states (Maryland, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06080698 about?
NCT06080698 is a clinical study titled "Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial". The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than rema...
What is the current status of trial NCT06080698?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,030 participants. The study started on 2024-02-22. Estimated completion is 2027-06-30.
What conditions does trial NCT06080698 study?
This clinical trial studies the following conditions: Gram-negative Bacteremia.
What interventions are being tested in trial NCT06080698?
The interventions under investigation include: Intravenous Antibiotics (DRUG), Oral Antibiotics (DRUG).
Who is sponsoring clinical trial NCT06080698?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06080698 being conducted?
This trial has 11 study locations across California, Colorado, Maryland, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06080698's enrollment target sits among peer trials
1,030 103rd of 2000 higher than 1,898 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI